Skip to Content
Merck
  • NRP1 presented in trans to the endothelium arrests VEGFR2 endocytosis, preventing angiogenic signaling and tumor initiation.

NRP1 presented in trans to the endothelium arrests VEGFR2 endocytosis, preventing angiogenic signaling and tumor initiation.

Developmental cell (2014-03-25)
Sina Koch, Laurens A van Meeteren, Eric Morin, Chiara Testini, Simone Weström, Hanna Björkelund, Sébastien Le Jan, Jeremy Adler, Philipp Berger, Lena Claesson-Welsh
ABSTRACT

Neuropilin 1 (NRP1) modulates angiogenesis by binding vascular endothelial growth factor (VEGF) and its receptor, VEGFR2. We examined the consequences when VEGFR2 and NRP1 were expressed on the same cell (cis) or on different cells (trans). In cis, VEGF induced rapid VEGFR2/NRP1 complex formation and internalization. In trans, complex formation was delayed and phosphorylation of phospholipase Cγ (PLCγ) and extracellular regulated kinase 2 (ERK2) was prolonged, whereas ERK1 phosphorylation was reduced. Trans complex formation suppressed initiation and vascularization of NRP1-expressing mouse fibrosarcoma and melanoma. Suppression in trans required high-affinity, steady-state binding of VEGF to NRP1, which was dependent on the NRP1 C-terminal domain. Compatible with a trans effect of NRP1, quiescent vasculature in the developing retina showed continuous high NRP1 expression, whereas angiogenic sprouting occurred where NRP1 levels fluctuated between adjacent endothelial cells. Therefore, through communication in trans, NRP1 can modulate VEGFR2 signaling and suppress angiogenesis.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Phospholipase C from Clostridium perfringens (C. welchii), Type XIV, lyophilized powder, ≥150 units/mg protein
Sigma-Aldrich
Phospholipase C from Clostridium perfringens (C. welchii), Type I, lyophilized powder, 10-50 units/mg protein
Sigma-Aldrich
Phospholipase C from Bacillus cereus, ≥200 units/mg protein